Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bjid.2021.101549 http://scihub22266oqcxt.onion/10.1016/j.bjid.2021.101549 33621543!7894091!33621543     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Braz+J+Infect+Dis 2021 ; 25 (2): 101549 Nephropedia Template TP {{tp|p=33621543|t=2021. Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 |pdf=|usr=}}{{33621543}} gab.com Text Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 JO: Braz J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33621543 #FOAvip OBJECTIVES: To assess the efficacy of hydroxychloroquine in combination with azithromycin in terms of clinical and biochemical outcomes in adult patients with COVID-19 hospitalized for acute respiratory distress syndrome (ARDS), and to describe the occurrence of adverse events. METHOD: Retrospective comparative study, based in a quaternary private hospital in Rio de Janeiro, Brazil, involving 193 adult patients hospitalized for mild and moderate COVID-19 related ARSD, analyzing treatment efficacy based on clinical and biochemical outcomes. RESULTS: The active group comprised 101 (52.3%) patients using hydroxychloroquine associated with azithromycin and the control group 92 (47.7%) patients who did not take these medications. Median age was 59 (47-70) in the active group and 65 (47-77) in the control group (p?<?0.05). Patients in the control group had greater extent of pulmonary involvement on baseline chest CT scans (p?<?0.05). All other baseline variables (BMI, comorbidities, previous use of medications and biochemical assessments) were similar between groups. In the medication group, 25% (25 out of 101) were admitted to the ICU, compared to 21% (19 out of 92) in the control group (p?>?0.05). No difference in mortality, duration of non-invasive oxygen use or duration of hospitalization was seen between groups. The therapeutic regimen was well tolerated, with only eight (7.9%) patients presenting gastrointestinal symptoms and eight (7.9%) patients withdrawn treatment due to QTc prolongation. CONCLUSIONS: Patients treated with hydroxychloroquine combined with azithromycin and the control group had similar clinical outcomes. This therapeutic regimen was considered ineffective in hospitalized patients with mild to moderate COVID-19 related ARDS and was associated with few non-severe adverse events. Twit Text FOAVip Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 ????Braz J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33621543 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33621543 #FOAvip English Wikipedia <ref>{{Cite pmid|33621543}}</ref> Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 #MMPMID33621543 Lamback EB; Oliveira MA; Haddad AF; Vieira AFM; Neto ALF; Maia TDS; Chrisman JR; Spineti PPM; Mattos MA; Costa E Braz J Infect Dis 2021[Mar]; 25 (2): 101549 PMID33621543show ga OBJECTIVES: To assess the efficacy of hydroxychloroquine in combination with azithromycin in terms of clinical and biochemical outcomes in adult patients with COVID-19 hospitalized for acute respiratory distress syndrome (ARDS), and to describe the occurrence of adverse events. METHOD: Retrospective comparative study, based in a quaternary private hospital in Rio de Janeiro, Brazil, involving 193 adult patients hospitalized for mild and moderate COVID-19 related ARSD, analyzing treatment efficacy based on clinical and biochemical outcomes. RESULTS: The active group comprised 101 (52.3%) patients using hydroxychloroquine associated with azithromycin and the control group 92 (47.7%) patients who did not take these medications. Median age was 59 (47-70) in the active group and 65 (47-77) in the control group (p??0.05). No difference in mortality, duration of non-invasive oxygen use or duration of hospitalization was seen between groups. The therapeutic regimen was well tolerated, with only eight (7.9%) patients presenting gastrointestinal symptoms and eight (7.9%) patients withdrawn treatment due to QTc prolongation. CONCLUSIONS: Patients treated with hydroxychloroquine combined with azithromycin and the control group had similar clinical outcomes. This therapeutic regimen was considered ineffective in hospitalized patients with mild to moderate COVID-19 related ARDS and was associated with few non-severe adverse events. |*COVID-19 Drug Treatment[MESH] |*Hydroxychloroquine/adverse effects[MESH] |Adult[MESH] |Azithromycin/adverse effects[MESH] |Brazil[MESH] |Drug Therapy, Combination[MESH] |Humans[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH]Hydroxychloroquine with azithromycin in patients hospitalized for mild(epmc).pdf DeepDyve Pubget Overpricing